Shares of the vaccine maker Moderna gained traction recently due to its updates of its vaccine trials with bang up results. Its innovation in its pharmaceutical division also sparked upward pressure on its share price.
Phase 3 Trial Results of Next-Generation COVID-19 vaccine:
Moderna recently released positive interim results of its Phase 3 trial of the next-generation COVID-19 vaccine candidate, the mRNA-1283. They are pleased to announce that the vaccine showed a higher immune response compared to their earlier vaccine, mRNA-1273.
Approval of RSV Vaccine:
Canada's health authorities gave a green light to Moderna's RSV vaccine, mResvia in adults of the age of 60 and older. The vaccine is the only pre-filled syringe RSV vaccine with distribution into the market in early 2025.
Partnership with Merck in NSCL Cancer Treatment:
Moderna and Merck have started exploring a Phase 3 trial of combining mRNA-4157 and KEYTRUDA for use in cases of non-small cell lung (NSCL) cancer post-treatment. Both organizations applaud the relationship in showing the possibilities of future cooperation and progress in eradicating several types of cancer.
These developments point to the fact that Moderna is poised for more growth and success in the years to come not only as it continues the battle against COVID-19 but also branching out into other areas such as RSV vaccine and cancer treatments.
You can make more informed investment decisions. Dive deeper into Moderna's performance with charts and guru insights by visiting GuruFocus now!
